Skip to main content
SpringerLink
Log in

Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics

  • Chapter
  • First Online:
Development of Antibody-Based Therapeutics

  • 2393 Accesses

Abstract

Population-based pharmacokinetic-pharmacodynamic (PK-PD) approaches have been successfully applied in various stages of drug development over the last few decades. The development of antibody-based therapeutics has benefited substantially from the utilization of population approaches. Moreover, almost all FDA-approved monoclonal antibody therapeutics have been evaluated using population approaches. In this chapter, application of population PK-PD methods will be reviewed in the context of translational strategies employed during the development of antibody-based therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aarons L (1999) Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 36:255–264

    Article  PubMed  CAS  Google Scholar 

  • Bauer RJ, Guzy S (2004) Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data. In: D’Argenio DZ (ed) Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Kluwer Academic Publishers, Boston, pp 135–163

    Chapter  Google Scholar 

  • Bauer RJ, Guzy S, Ng C (2007) A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 9:E60–E83

    Article  PubMed  Google Scholar 

  • Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8:195–222

    PubMed  CAS  Google Scholar 

  • Betts AM, Clark TH, Yang J, Treadway JL, Li M et al (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2–13

    Article  PubMed  CAS  Google Scholar 

  • Coiffier B, Losic N, Ronn BB, Lepretre S, Pedersen LM et al (2010) Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study. Br J Haematol 150:58–71

    PubMed  CAS  Google Scholar 

  • Dartois C, Freyer G, Michallet M, Henin E, You B et al (2007) Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clin Pharmacokinet 46:417–432

    Article  PubMed  CAS  Google Scholar 

  • Davidian M, Giltinan DM (1995) Nonlinear models for repeated measurement data. Chapman and Hall, New York

    Google Scholar 

  • Davidian M, Giltinan DM (2003) Nonlinear models for repeated measurement data: an overview and update. J Agr Biol Environ Stat 8:387–419

    Article  Google Scholar 

  • Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–478

    Article  PubMed  CAS  Google Scholar 

  • Duan JZ (2007) Applications of population pharmacokinetics in current drug labelling. J Clin Pharm Ther 32:57–79

    Article  PubMed  CAS  Google Scholar 

  • Ette EI, Kelman AW, Howie CA, Whiting B (1995) Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm 23:551–566

    Article  PubMed  CAS  Google Scholar 

  • Ette EI, Sun H, Ludden TM (1998) Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol 38:417–423

    PubMed  CAS  Google Scholar 

  • Ette EI, Williams PJ (2004) Population pharmacokinetics II: estimation methods. Ann Pharmacother 38:1907–1915

    Article  PubMed  CAS  Google Scholar 

  • Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J et al (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65:1211–1228

    Article  PubMed  CAS  Google Scholar 

  • Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ (1993) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37:1065–1072

    PubMed  CAS  Google Scholar 

  • Frey N, Grange S, Woodworth T (2010) Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 50:754–766

    Article  PubMed  CAS  Google Scholar 

  • Guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling (ed) (2006) UFCfDEaR [CDER]. Rockville

    Google Scholar 

  • Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ (2007) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63:548–561

    Article  PubMed  CAS  Google Scholar 

  • Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L et al (2010) Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 87:497–503

    Article  PubMed  CAS  Google Scholar 

  • Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493–507

    Article  PubMed  CAS  Google Scholar 

  • Kovarik JM, Pescovitz MD, Sollinger HW, Kaplan B, Legendre C et al (2001) Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 15:123–130

    Article  PubMed  CAS  Google Scholar 

  • Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K et al (2009) In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 206:1029–1036

    Article  PubMed  CAS  Google Scholar 

  • Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J et al (2006) Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66:7630–7638

    Article  PubMed  CAS  Google Scholar 

  • Lee JI, Zhang L, Men AY, Kenna LA, Huang SM (2010) CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 49:295–310

    Article  PubMed  CAS  Google Scholar 

  • Lindstrom ML, Bates DM (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46:673–687

    Article  PubMed  CAS  Google Scholar 

  • Lowe PJ, Tannenbaum S, Gautier A, Jimenez P (2009) Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68:61–76

    Article  PubMed  CAS  Google Scholar 

  • Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J (2010) On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 106:195–209

    Article  PubMed  CAS  Google Scholar 

  • Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786

    Article  PubMed  CAS  Google Scholar 

  • Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D (2002) Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn 29:271–307

    Article  PubMed  CAS  Google Scholar 

  • Ma P, Yang BB, Wang YM, Peterson M, Narayanan A et al (2009) Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 49:1142–1156

    Article  PubMed  CAS  Google Scholar 

  • Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532

    Article  PubMed  CAS  Google Scholar 

  • Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1–10

    Article  PubMed  CAS  Google Scholar 

  • Meno-Tetang GM, Lowe PJ (2005) On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96:182–192

    Article  PubMed  CAS  Google Scholar 

  • Mentre F, Gomeni R (1995) A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat 5:141–158

    Article  PubMed  CAS  Google Scholar 

  • Mentre F, Kovarik J, Gerbeau C (1999) Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. J Pharmacokinet Biopharm 27:213–230

    Article  PubMed  CAS  Google Scholar 

  • Monolix Users Manual (2008) Orsay. Laboratorie de Mathematiques, U. Paris-Sue, France

    Google Scholar 

  • Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S et al (2007) Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 64:278–291

    Article  PubMed  CAS  Google Scholar 

  • Ng CM, Bruno R, Combs D, Davies B (2005a) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792–801

    Article  PubMed  CAS  Google Scholar 

  • Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ (2005b) Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22:1088–1100

    Article  PubMed  CAS  Google Scholar 

  • Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW (2010) Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemother Pharmacol 65(2):207–217

    Google Scholar 

  • Pillai GC, Mentre F, Steimer JL (2005) Non-linear mixed effects modeling—from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 32:161–183

    Article  PubMed  CAS  Google Scholar 

  • Pinheiro JC, Bates DM (1995) Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Stat 4:12–35

    Article  Google Scholar 

  • SAS/STAT 9.2 User’s Guide: The NLMXED procedure (2008) SAS Insititute Inc., Cary

    Google Scholar 

  • Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5:411–459

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445–479

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL (1980) Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8:553–571

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL (1981) Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9:635–651

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL (1982) Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 71:1344–1348

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL (1983) Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 11:303–319

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291

    Article  PubMed  CAS  Google Scholar 

  • Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ (2009) Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 123(107–113):e103

    Google Scholar 

  • Steimer JL, Mallet A, Golmard JL, Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265–292

    Article  PubMed  CAS  Google Scholar 

  • Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L (2009) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14:298–305

    Article  PubMed  CAS  Google Scholar 

  • Vugmeyster Y, Tian X, Szklut P, Kasaian M, Xu X (2009) Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys. Pharm Res 26:306–315

    Article  PubMed  CAS  Google Scholar 

  • Wang DD, Zhang S, Zhao H, Men AY, Parivar K (2009) Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 49:1012–1024

    Article  PubMed  CAS  Google Scholar 

  • Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558

    Article  PubMed  CAS  Google Scholar 

  • Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ et al (2010) Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9 m and hepcidin in cynomolgus monkeys. AAPS J 12:646–657

    Article  PubMed  CAS  Google Scholar 

  • Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P et al (2008) Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 48:681–695

    Article  PubMed  CAS  Google Scholar 

  • Xu Z, Vu T, Lee H, Hu C, Ling J et al (2009) Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 49:1056–1070

    Article  PubMed  CAS  Google Scholar 

  • Zhang X, Achmitt S, Grange S (2009) Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo. Clin Pharmacol Ther 85:S59

    Article  Google Scholar 

  • Zhou H (2006) Population-based assessments of clinical drug–drug interactions: qualitative indices or quantitative measures? J Clin Pharmacol 46:1268–1289

    Article  PubMed  CAS  Google Scholar 

  • Zhou H, Hu C, Zhu Y, Lu M, Liao S et al (2009) Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 50:257–267

    PubMed  Google Scholar 

  • Zhu Y, Hu C, Lu M, Liao S, Marini JC et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162–175

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PK/PD and in vivo Pharmacology, Merck Research Laboratory—Palo Alto, 901 South California Ave, Palo Alto, CA, 94304, USA

    Feng Jin

Authors
  1. Feng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng Jin .

Editor information

Editors and Affiliations

  1. Merck Research Laboratory, Merck & CO Inc., California Avenue 901, Palo Alto, 94304, California, USA

    Mohammad A. Tabrizi

  2. Pfizer CTI- New York, East 29th Street 450, New York, 10016, New York, USA

    Gadi G. Bornstein

  3. Takeda California, Inc., E. Grand Avenue 285, South San Francisco, 94080, California, USA

    Scott L. Klakamp

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jin, F. (2012). Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics. In: Tabrizi, M., Bornstein, G., Klakamp, S. (eds) Development of Antibody-Based Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5955-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5955-3_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-5953-9

  • Online ISBN: 978-1-4419-5955-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation